STAT+: ‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Though a rival’s Alzheimer’s drug reached the market first, the CEO of Eli Lilly spoke confidently Tuesday about its amyloid-clearing product’s potential to take on Biogen’s recently launched Aduhelm.

Speaking at STAT’s Breakthrough Science Summit, CEO David Ricks said Lilly last month asked the Food and Drug Administration to expedite approval of its drug donanemab for “business reasons, competitive reasons, but more importantly, patient reasons.” 

Continue to STAT+ to read the full story…

STAT+: ‘Aduhelm left room’: Lilly CEO eyes competition with Biogen Alzheimer’s drug

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top